<DOC>
	<DOCNO>NCT00530101</DOCNO>
	<brief_summary>The purpose research study evaluate MR image subject receive doxorubicin chemotherapy see MR detect heart damage well well MUGA scan . This research study expect enroll approximately 10 subject 12 month University Miami / Miller School Medicine .</brief_summary>
	<brief_title>The Magnetic Resonance Imaging Evaluation Doxorubicin Cardiotoxicity</brief_title>
	<detailed_description>Doxorubicin ( Adriamycin ) one widely use chemotherapy agent , despite well-known causation cardiac toxicity . Doxorubicin cause apoptotic cell death , show uptake antimyosin antibody nuclear medicine study ( 1,2 ) . Myocyte damage dose-related , produce leave ventricular dysfunction may lead clinically significant heart failure , especially patient limited cardiac reserve . An estimated 7 % patient develop doxorubicin-related congestive heart failure ( CHF ) cumulative dose 550 mg/m2 ( 3 ) . Methods detect prevent doxorubicin-induced cardiotoxicity investigate year . Serial evaluation leave ventricular function use Multigated Acquisition ( MUGA ) scan ( radionuclide angiocardiography ) propose 20 year ago one method detect cardiotoxicity ( 4 ) . More sophisticated nuclear imaging ( PET ) able demonstrate early change cardiotoxicity ( 5 ) . There number potential indicator early cardiotoxicity toxic effect right ventricle leave ventricular diastolic ( vs. systolic ) function MUGA optimally suit demonstrate . Even earlier , image manifestation cell death could provide first clue impend cardiotoxicity ( 1,2,6 ) . Cardiac MR ( CMR ) potential address facet doxorubicin toxicity . Biventricular function assess cine image , CMR well-established highly reliable method cardiac functional assessment . Of even great potential interest , cell injury death demonstrate use gadolinium enhancement , myocardial infarction ( focal enhancement ) well myocarditis ( focal diffuse enhancement ) ( 7,8 ) . Doxorubicin toxicity may fact share pathophysiological characteristic myocarditis ( 9 ) . It hypothesis CMR able show functional cellular ( infarct , microinfarct , myocarditis-type ) effect doxorubicin toxicity determine conclusion doxorubicin therapy . Specifically , hypothesize myocardial tissue demonstrate great increase signal ( decrease T1 contrast administration ) chemotherapy compare chemotherapy . Methods 1 . Patient Selection : Ten patient select receive doxorubicin breast cancer treatment recruit Oncology Services Sylvester Cancer Center Jackson Memorial Hospital . This pilot study select patient increase likelihood develop cardiotoxicity , due borderline cardiac function baseline , advanced age , anticipation high cumulative dose administer doxorubicin . Patients receive radiation therapy leave chest chemotherapy ( i.e. , leave breast cancer ) exclude eliminate possible cardiotoxic effect radiation . CMR study perform charge patient , support sponsor study . CMR image subject IRB approval , informed consent , HIPAA regulation . Contrast-enhanced CMR obtain three time point : 1 . Prior first dose doxorubicin ( image characteristic serve control value indicate later change ) . 2 . After first cycle doxorubicin . 3 . At conclusion therapy , typically 4-6 cycle ; cumulative dose 360 600 mg/m2 doxorubicin . In addition standard screen contraindication MR imaging , patient evaluate estimated Glomerular Filtration Rate ( GFR ) within 30 day prior MR scan . This avoid rare potential complication Nephrogenic Systemic Fibrosis patient severe end-stage renal failure receive gadolinium MR contrast ( 10 ) . GFR calculate serum creatinine , patient age , gender , race , use MDRD GFR Calculator ( Stephen Z. Fadem , M.D . ) : http : //www.kidney.org/professionals/kdoqi/gfr_calculator.cfm Patients undergo contrast-enhanced MR unless calculate GFR equal great 60 mL/min/1.73 m2 2 . Imaging : CMR perform Siemens 1.5T Sonata locate University Miami Outpatient Diagnostic Imaging Center . It anticipate scan require approximately 60 minute . Three image plane ( short axis [ SA ] series ventricle , individual 4 chamber [ 4CV ] 2 chamber [ 2CV ] view ) utilized . Sequences consist : A. Precontrast imaging : 1 . T1-weighted ( SA series ) 2 . TI scout ( single mid-ventricular SA ) [ The TI scout sequence obtains image multiple inversion ( TI ) time single slice level ] 3 . TrueFISP cine gradient echo imaging ( SA series , 2CV , 4CV ) B. Postcontrast imaging : 0.1 mmol/kg OptiMARK intravenous 1 . 1 minute post-injection : TI scout ( single mid-ventricular SA ) 2 . 2-4 minute post-injection : Turboflash inversion recovery ( single mid-ventricular SA ) serial TI value determine time myocardial nulling 3 . 5 minute post-injection : TI scout ( single mid-ventricular SA ) 4 . 6-9 minute post-injection : Turboflash inversion recovery ( single mid-ventricular SA ) serial TI value determine time myocardial nulling 5 . 10-14 minute post-injection : Segmented IR delay image use TI myocardial signal nulling ( SA series , 2CV , 4CV ) 6 . 15 minute post-injection : TI scout ( single mid-ventricular SA ) 7 . 16-19 minute post-injection : Turboflash inversion recovery ( single mid-ventricular SA ) serial TI value determine time myocardial nulling 8 . 20 minute post-injection : TI scout ( single mid-ventricular SA ) 9 . 21 minute post-injection : T1-weighted ( SA series ) 3 . Analysis : ANOVA use assess difference measure value discrete variable list A , B , C , D . Data analyze three image session together use ANOVA , pair session ( pretreatment vs. first cycle doxorubicin , first cycle doxorubicin vs. maximum cumulative dose , pretreatment vs. maximum cumulative dose ) use pair t-test ( Wilcoxon signed-rank test variance unequal ) . The MR image set analyze random order . A. TrueFISP cine : analysis utilize ARGUS software package Siemens system . End-diastolic end-systolic endocardial contour generate use semi-automated technique whereby initial manual contouring follow automated contour generation , manually edit final calculation perform . 1 . Ejection fraction ( biventricular ) ventricular volume ( end-systole end-diastole ) . 2 . Diastolic leave ventricular function I . 1/3 peak fill rate ( PFR ) II . 1/3 fill fraction ( 1/3 FF ) 3 . Wall motion : The AHA 17-segment model utilized ( 6 segment basal , mid-ventricular , near-apical level , single apical segment ) . A five-point scale assign segment ( normal , mildly hypokinetic , severely hypokinetic , akinetic , dyskinetic ) . Summed value yield single measure contractility imaging study . B. T1-weighted Region-of-interest signal intensity myocardium measure mid-left ventricular free wall , mid-interventricular septum , skeletal muscle precontrast postcontrast T1-weighted imaging . We calculate variable represent `` percent enhancement '' location follow : % enhancement = signal intensity ( postcontrast ) - signal intensity ( precontrast ) signal intensity ( precontrast ) C. The TI scout image set provide single TI value optimal myocardial nulling well exponential curve reflect T1 recovery myocardium time point acquisition ( precontrast , 1 minute postcontrast , 5 minute postcontrast , 15 minute postcontrast , 20 minute postcontrast ) . The TI scout perform multiple time point due dynamic nature tissue enhancement gadolinium administration . D. The turboflash inversion recovery image ( mid-ventricular ) provide alternative single TI value optimal myocardial nulling time point acquisition ( 2-4 minute , 6-9 minute , 16-19 minute postinjection ) . The turboflash inversion recovery image perform multiple time point due dynamic nature tissue enhancement gadolinium administration . E. Segmented IR delay image provide image entire myocardium evaluate focal myocardial signal hyperintensities , whether due infarction myocarditis . The optimum TI value determine ( D ) use . If identify , lesion manually contour use irregular region interest tool console . The infarct size calculate total infarct area multiply section thickness specific gravity ( assume 1.05 g/mL ) myocardium . Medical record provide data regard cardiac morbidity mortality .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Subject must breast cancer undergo radiation treatment likelihood develop cardiotoxicity . Healthy subject Males Subjects age 18</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>